Major Chinese API and generic-drug manufacturer with a long-standing Pfizer joint venture and broad export APIs business.
Major Chinese API and generic-drug manufacturer with a long-standing Pfizer joint venture and broad export APIs business.
Sells fermentation-based ingredients and finished generics, with domestic hospital sales exposed to China's volume-based procurement, where winners of government tenders sell at much lower prices, and exports to overseas generics makers. A 2012 joint venture with Pfizer produces and markets generics in China.
Moat: narrow (scale, regulatory licence). Large-scale, FDA/EU-audited API manufacturing plus a long Pfizer joint-venture relationship.
Headquarters: Taizhou, Zhejiang, China · Employees: 8,751
Size Zhejiang Hisun Pharmaceutical (600267.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.19B, the 1093rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.67 on 18 Nov 2026.
Performance Over six months the shares gained 13.5%, against -4.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 7.0% over the last twelve months (peer median +5.0%); the operating margin is 15.3% (peer median 11.1%).
Valuation It trades at 15.0× forward earnings against a peer median of 21.6× (4th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.4 points above its cost of capital (5.6% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥9.15B | CN¥10.5B | CN¥10.3B | CN¥10.3B | CN¥12.0B |
| Revenue growth | — | +2% | 0% | -14% | — |
| Gross profit | CN¥5.42B | CN¥4.26B | CN¥3.81B | CN¥3.65B | CN¥4.47B |
| EBITDA | n/a | CN¥2.08B | CN¥1.84B | CN¥1.34B | CN¥2.00B |
| Net income | CN¥1.23B | CN¥541M | CN¥601M | -CN¥93.2M | CN¥489M |
| Free cash flow | CN¥1.09B | CN¥1.67B | CN¥1.96B | CN¥1.28B | CN¥1.55B |
| Capital expenditure | CN¥503M | CN¥376M | CN¥238M | CN¥240M | CN¥531M |
| Total debt | CN¥1.71B | CN¥3.22B | CN¥4.50B | CN¥6.20B | CN¥7.16B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
| Apeloa Pharmaceutical 000739.SZ | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% |
| Zhejiang Medicine 600216.SS | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% |
| North China Pharmaceutical 600812.SS | $1.08B | -12% | -21% | 5% | n/a | 1.0% |
| Cspc Pharma 1093.HK | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% |
| Zhejiang NHU 002001.SZ | $11.8B | -22% | +11% | 33% | 9.7× | -8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600267.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | -5.4% | 11th highest of 21 |
| 6-month return | +13.5% | -4.9% | 6th highest of 21 |
| Distance from 52-week high | -15.5% | -29.6% | 5th highest of 21 |
| Revenue growth (TTM) | -7.0% | +5.0% | 4th lowest of 20 |
| Operating margin | 15.3% | 11.1% | 7th highest of 19 |
| Forward P/E | 15.0× | 21.6× | 4th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -9.7% | 2.8% | 3rd least demanding of 15 |
| Growth delivered (Del g) | -1.5% | +13.1% | 2nd lowest of 15 |
| Hurdle (Req g minus delivered) | -8.2 pp | -0.1 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +9.4 pp | -1.2 pp | 4th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |